



Anti-SARS-CoV-2/COVID-19 Drugs and Vaccines

Guest Editors:

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport,
Victoria University, Melbourne,
VIC 3011, Australia

Dr. Majid Davidson

Institute of Health and Sports,
Victoria University, Melbourne,
VIC 3011, Australia

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Dear Colleagues,

A novel strain of coronavirus, SARS-CoV-2, the causative agent of coronavirus disease (COVID-19) was first identified in late 2019 and triggered a pandemic which has been ongoing since March 2020. The development of effective therapeutics is an urgent global priority to stop the spread of COVID-19 infections and prevent further fatalities. As such, a number of platforms such as drugs, vaccines, monoclonal antibodies, pharmacological therapy, plasma therapy, immune boosters, and alternative medicines have been explored.

In this Special Issue of *Biologics*, the focus will be on the development of vaccines, pharmacological therapy, alternative medicines, monoclonal antibodies, plasma therapy, preclinical studies, clinical trials, replication, viral life cycle, and pathogenesis of SARS-CoV-2, as well as areas of identification of novel drug targets and any form of treatment models against COVID-19 infection. In vitro, in vivo, in silico, preclinical, and clinical trials are all welcome.

This Special Issue is for reviews or original research papers on biologics against the SARS-CoV-2 virus/COVID-19.

